{"id":603421,"date":"2022-06-08T19:02:01","date_gmt":"2022-06-08T19:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=603421"},"modified":"2022-06-08T19:02:01","modified_gmt":"2022-06-08T19:02:01","slug":"chronic-idiopathic-urticaria-market-size-epidemiology-pipeline-therapies-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-idiopathic-urticaria-market-size-epidemiology-pipeline-therapies-companies-and-competitive-analysis-by-delveinsight_603421.html","title":{"rendered":"Chronic Idiopathic Urticaria Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1654675484.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Idiopathic Urticaria Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1654675484.jpeg\" alt=\"Chronic Idiopathic Urticaria Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Chronic Idiopathic Urticaria Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">Chronic idiopathic urticaria (CIU) is a distressing skin condition that causes red, swollen, itchy and sometimes painful hives or &ldquo;wheals&rdquo; on the skin. It is being associated with autoimmunity in almost half of the cases but the remaining cases still remains &ldquo;idiopathic&rdquo; and all are considered spontaneous. Therefore, the term chronic spontaneous urticaria (CSU) has been employed to indicate chronic urticaria that is endogenous, and independent of any external physical stimulus, which is conceptually helpful, and does not imply knowing or not-knowing the cause.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &#8220;<strong>Chronic Idiopathic Urticaria Market Insights, Epidemiology, and Market Forecast-2032<\/strong>&#8221; report delivers an in-depth understanding of the Chronic Idiopathic Urticaria, historical and forecasted epidemiology as well as the Chronic Idiopathic Urticaria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-idiopathic-urticaria-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Chronic Idiopathic Urticaria Market<\/strong><\/a><strong> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>According to the study by Zuberbier T et al., 2010; lifetime prevalence for Chronic Urticaria was 1.8%. Women were more likely than men to have Chronic Urticaria (70.3% vs. 29.7%). The lifetime prevalence of urticaria: 7.8% (Germany). The estimates in the existing literature for the prevalence of CU range from 0.05% to 3%.<\/li>\n<li>According to the study of Reham Ezz El-Dawla El-Sharkawy et al., 2018; the incidence of CU has been estimated at 1.4% per year in the USA with male to female ratio at 1: 3.7. Out of 108 patients, 58.3% were affected with CSU.<\/li>\n<li>According to the study by Marcus Maurer et al., 2017; the estimated point prevalence of CIU is approximately 0.5% to 1% worldwide.<\/li>\n<li>The first-line management of acute or chronic urticaria is focused on the use of H1 antihistamines, leukotriene antagonists and\/or H2 receptor antagonists next. However, in Europe, treatment with sedating H1 antihistamines and H2 antihistamines are not recommended. Along with these there are few FDA approved therapy for treatment of CIU.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-idiopathic-urticaria-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/chronic-idiopathic-urticaria-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-idiopathic-urticaria-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Chronic Idiopathic Urticaria Market<\/strong><\/a>&nbsp;<strong>Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Chronic Idiopathic Urticaria, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.<\/li>\n<li>Comprehensive insight has been provided into the Chronic Idiopathic Urticaria epidemiology and treatment in the 7MM.<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Idiopathic Urticaria is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.<\/li>\n<li>A detailed review of the Chronic Idiopathic Urticaria market; historical and forecasted is included in the report, covering drug outreach in the 7MM.<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Idiopathic Urticaria market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Chronic Idiopathic Urticaria Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novartis<\/li>\n<li>Genentech<\/li>\n<li>Kiniksa pharmaceuticals<\/li>\n<li>UCB Inc.<\/li>\n<li>Merck Sharp &amp; Dohme Corp.<\/li>\n<li>Sanofi-aventis<\/li>\n<li>And Many Others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-idiopathic-urticaria-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/chronic-idiopathic-urticaria-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-idiopathic-urticaria-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Chronic Idiopathic Urticaria Drugs<\/strong><\/a><strong>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Xolair (omalizumab)<\/li>\n<li>XYZAL (levocetirizine dihydrochloride)<\/li>\n<li>CLARINEX (Desloratadine)<\/li>\n<li>Allegra (fexofenadine hydrochloride)<\/li>\n<li>Ligelizumab<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Chronic Idiopathic Urticaria<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Chronic Idiopathic Urticaria<\/p>\n<p style=\"text-align: justify;\">4. Chronic Idiopathic Urticaria: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Chronic Idiopathic Urticaria: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Chronic Idiopathic Urticaria Treatment<\/p>\n<p style=\"text-align: justify;\">11. Marketed Products<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">12. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">13. Chronic Idiopathic Urticaria: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Chronic Idiopathic Urticaria<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">20.1. Bibliography<\/p>\n<p style=\"text-align: justify;\">20.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Delveinsight:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-idiopathic-urticaria-market-size-epidemiology-pipeline-therapies-companies-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-idiopathic-urticaria-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/chronic-idiopathic-urticaria-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/chronic-idiopathic-urticaria-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-idiopathic-urticaria-market-size-epidemiology-pipeline-therapies-companies-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chronic Idiopathic Urticaria Market Chronic idiopathic urticaria (CIU) is a distressing skin condition that causes red, swollen, itchy and sometimes painful hives or &ldquo;wheals&rdquo; on the skin. It is being associated with autoimmunity in almost half of the cases but &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-idiopathic-urticaria-market-size-epidemiology-pipeline-therapies-companies-and-competitive-analysis-by-delveinsight_603421.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,404,416],"tags":[],"class_list":["post-603421","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/603421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=603421"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/603421\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=603421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=603421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=603421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}